Clinical trials located in


Grzepnica city is located in Poland. Currently, 5 clinical trials are being conducted in this city.

Grzepnica, a village in northwestern Poland, is nestled within the West Pomeranian Voivodeship, under the administrative jurisdiction of Gmina Dobra, Police County. Historically significant, it was first mentioned in documents from 1224, showcasing its long-standing presence in the region. Despite its modest size, Grzepnica is surrounded by picturesque landscapes, making it a serene location. The village is characterized by its tranquil rural atmosphere, traditional Polish architecture, and a close-knit community that preserves the area’s rich cultural heritage.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of AZD5305 and drug combinations for patients with advanced cancers

    This study concerns several types of advanced solid tumors, including ovarian, breast, pancreatic, prostate, non-small cell lung, colorectal, bladder, gastric, biliary, cervical, and endometrial cancers, as well as small cell lung cancer. The therapy involves the experimental drug AZD5305, which is a type of PARP inhibitor. A PARP inhibitor is a substance that blocks an enzyme (PARP) used by cells to repair damage to their DNA. Blocking PARP can help prevent cancer cells from repairing their damaged DNA, leading to cell death.

    The study will test AZD5305 alone and in combination with other anti-cancer agents, including Paclitaxel, Carboplatin, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd), and Camizestrant.

    The purpose of the study is to determine if AZD5305, alone or with these other drugs, is safe, tolerable, and effective in treating patients with these types of cancer.

    Patients will receive AZD5305 either as monotherapy (on its own) or alongside the specified anti-cancer agents in different modules of the study. Some modules will include dose-escalation parts to find the best dose with the least side effects, followed by expansion parts to further test the effectiveness.

    Each module will look at how well the treatment works and track any side effects that occur, with a special focus on serious or unusual side effects. This study aims to provide new insights into the effectiveness of combination therapies involving AZD5305 for individuals with advanced solid tumors.

    • trastuzumab deruxtecan
    • Saruparib
    • camizestrant
    • Dato-DXd
    • Carboplatin
    • Paclitaxel
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland: